• Something wrong with this record ?

Cationic nonsymmetric transplatinum complexes with piperidinopiperidine ligands. Preparation, characterization, in vitro cytotoxicity, in vivo toxicity, and anticancer efficacy studies

Y Najajreh, E Khazanov, S Jawbry, Y Ardeli-Tzaraf, JM Perez, J Kasparkova, V Brabec, Y Barenholz, D Gibson

. 2006 ; 49 (15) : 4665-4673.

Language English Country United States

Document type Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc14047231

Grant support
NR8562 MZ0 CEP Register

A series of complexes of the general formula trans-[PtCl2(Am)(pip-pip)] x HCl where pip-pip is 4-piperidinopiperidine and Am is NH3, methylamine (MA), dimethylamine (DMA), n-propylamine (NPA), isopropylamine (IPA), n-butylamine (NBA), or cyclohexylamine (CHA) were prepared and characterized, and their cytotoxic properties against ovarian and colon cancer cells were evaluated. The trans-[PtCl2(NH3)(pip-pip)] x HCl was significantly more potent than cisplatin in all the cisplatin-resistant ovarian cancer cell lines and was nearly as cytotoxic as cisplatin against colon cancer cells. In vivo studies in mice showed that the pip-pip complexes are significantly less toxic than cisplatin. Cisplatin was more efficacious than both trans-[PtCl2(NH3)(pip-pip)] x HCl and trans-[PtCl2(NBA)(pip-pip)] x HCl in the A2780 and A2780cisR tumor xenograft models, consistent with its lower IC50 values in A2780 cells but contrary to the higher IC50 values in A2780cisR cells. In the colon cancer cell studies, trans-[PtCl2(NH3)(pip-pip)] x HCl was slightly less potent than cisplatin in the in vitro studies but had efficacy comparable to that of cisplatin in the in vivo xenograft model.

000      
00000naa a2200000 a 4500
001      
bmc14047231
003      
CZ-PrNML
005      
20140310144736.0
007      
ta
008      
140224s2006 xxua f 000 0|eng||
009      
AR
035    __
$a (PubMed)16854072
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Najajreh, Yousef $u Department of Medicinal Chemistry and Natural Products, Faculty of Pharmacy, Al-Quds University, P.O. Box 20002, Jerusalem, Palestine.
245    10
$a Cationic nonsymmetric transplatinum complexes with piperidinopiperidine ligands. Preparation, characterization, in vitro cytotoxicity, in vivo toxicity, and anticancer efficacy studies / $c Y Najajreh, E Khazanov, S Jawbry, Y Ardeli-Tzaraf, JM Perez, J Kasparkova, V Brabec, Y Barenholz, D Gibson
520    9_
$a A series of complexes of the general formula trans-[PtCl2(Am)(pip-pip)] x HCl where pip-pip is 4-piperidinopiperidine and Am is NH3, methylamine (MA), dimethylamine (DMA), n-propylamine (NPA), isopropylamine (IPA), n-butylamine (NBA), or cyclohexylamine (CHA) were prepared and characterized, and their cytotoxic properties against ovarian and colon cancer cells were evaluated. The trans-[PtCl2(NH3)(pip-pip)] x HCl was significantly more potent than cisplatin in all the cisplatin-resistant ovarian cancer cell lines and was nearly as cytotoxic as cisplatin against colon cancer cells. In vivo studies in mice showed that the pip-pip complexes are significantly less toxic than cisplatin. Cisplatin was more efficacious than both trans-[PtCl2(NH3)(pip-pip)] x HCl and trans-[PtCl2(NBA)(pip-pip)] x HCl in the A2780 and A2780cisR tumor xenograft models, consistent with its lower IC50 values in A2780 cells but contrary to the higher IC50 values in A2780cisR cells. In the colon cancer cell studies, trans-[PtCl2(NH3)(pip-pip)] x HCl was slightly less potent than cisplatin in the in vitro studies but had efficacy comparable to that of cisplatin in the in vivo xenograft model.
590    __
$a bohemika - dle Pubmed
650    02
$a aminy $x chemie $7 D000588
650    02
$a zvířata $7 D000818
650    12
$a protinádorové látky $x farmakokinetika $x farmakologie $x chemická syntéza $x toxicita $7 D000970
650    02
$a nádorové buněčné linie $7 D045744
650    02
$a buněčné jádro $x genetika $7 D002467
650    02
$a nádory tračníku $7 D003110
650    02
$a DNA $x metabolismus $7 D004247
650    02
$a screeningové testy protinádorových léčiv $7 D004354
650    02
$a ženské pohlaví $7 D005260
650    02
$a glukosa $x farmakologie $7 D005947
650    02
$a lidé $7 D006801
650    02
$a ligandy $7 D008024
650    02
$a myši $7 D051379
650    02
$a myši inbrední BALB C $7 D008807
650    02
$a myši inbrední C57BL $7 D008810
650    02
$a myši nahé $7 D008819
650    12
$a organoplatinové sloučeniny $x farmakokinetika $x farmakologie $x chemická syntéza $x toxicita $7 D009944
650    02
$a nádory vaječníků $7 D010051
650    12
$a piperidiny $x farmakokinetika $x farmakologie $x chemická syntéza $x toxicita $7 D010880
650    02
$a chlorid sodný $x farmakologie $7 D012965
650    02
$a rozpustnost $7 D012995
650    02
$a rozpouštědla $7 D012997
650    02
$a vztahy mezi strukturou a aktivitou $7 D013329
650    02
$a transplantace heterologní $7 D014183
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Khazanov, Elena
700    1_
$a Jawbry, Seba
700    1_
$a Ardeli-Tzaraf, Yael $7 gn_A_00008165
700    1_
$a Perez, Jose Manuel
700    1_
$a Kašpárková, Jana, $d 1969- $7 xx0068609
700    1_
$a Brabec, Viktor, $d 1944- $7 jo20010087133
700    1_
$a Barenholz, Yechezkel
700    1_
$a Gibson, Dan
773    0_
$t Journal of Medicinal Chemistry $x 0022-2623 $g Roč. 49, č. 15 (2006), s. 4665-4673 $p J Med Chem $w MED00010049
910    __
$a ABA008 $b A 3173 $y 4 $z 0
990    __
$a 20140224154123 $b ABA008
991    __
$a 20140310144744 $b ABA008
999    __
$a ok $b bmc $g 1014251 $s 845773
BAS    __
$a 3
BMC    __
$a 2006 $b 49 $c 15 $d 4665-4673 $x MED00010049 $i 0022-2623 $m Journal of medicinal chemistry $n J Med Chem
GRA    __
$a NR8562 $p MZ0
LZP    __
$a NLK 2014-02/lpbo

Find record

Citation metrics

Archiving options